The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Chronic Hepatitis C Sufferers Might Benefit from Eurythmy

Back to News Homepage

Next

Nitazoxanide and IC41 Take on Interferon and Ribavirin

Unique Oral Drug Combo Acknowledged as Potential Hepatitis C Therapy

October 21, 2010

Print this page

A small study found that combining two oral drugs (not including interferon or ribavirin) demonstrated potential in treating Hepatitis C without many serious adverse events.

Combination of Two Oral Drugs Shows Promise for HCV in Small Study

By: Denise Napoli, Internal Medicine News Digital Network

10/14/10

A combination of two oral drugs for reducing viral load in hepatitis C patients had good safety and tolerability in a small, phase I study.

The finding, published online Oct. 15 in the Lancet, points the way toward an alternative to the current standard of care – subcutaneous pegylated interferon-alfa plus oral ribavirin – which has limited tolerability and efficacy.

The novel therapies that were tested in this study are RG7128, a nucleoside polymerase inhibitor, and danoprevir, a protease inhibitor, wrote Dr. Edward J. Gane of Auckland (New Zealand) Clinical Studies Ltd., an early-phase clinical pharmacology unit, and his colleagues.

Continue reading this entire article:
http://www.ehospitalistnews.com/index.php?id=100713&tx_ttnews[tt_news]=17726&cHash=2a3ae0a84f1347077ef1bba9131ce97b

No Comments - be the first!
Share
Share

Previous

Chronic Hepatitis C Sufferers Might Benefit from Eurythmy

Back to News Homepage

Next

Nitazoxanide and IC41 Take on Interferon and Ribavirin

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.